Antibiotics that Indian doctors have prescribed for years are now failing against a large share of common infections, from urinary tract infections to typhoid and bacterial diarrhoea, according to the 2025 annual report of the Indian Council of Medical Research (ICMR) Antimicrobial Resistance Surveillance and Research Network (AMRSN). The report, covering hospital laboratory data from 1 January to 31 December 2025, was put up on ICMR's website in New Delhi this week, and its findings were reported on 18 November 2026.
The ninth edition of the report draws on 1,13,008 culture-positive samples from 30 large tertiary-care hospitals and, for the first time, 20,529 samples from 34 smaller secondary-care hospitals, including 12 district hospitals.
Which common infections are becoming harder to treat?
Urinary tract infections caused by E. coli, bloodstream and hospital infections caused by Klebsiella pneumoniae, and typhoid and bacterial diarrhoea when treated with fluoroquinolones such as ciprofloxacin are among the clearest problem areas, the ICMR-AMRSN Annual Report 2025 shows.
- E. coli: The most commonly isolated germ in large hospitals (24.4% of samples). Only 18.4% of samples responded to cefotaxime and 24.7% to ceftazidime, two widely used third-generation cephalosporins. Low susceptibility was seen even in outpatients, which the report says suggests such resistance is widespread in the community.
- Klebsiella pneumoniae: Only 35–40% of samples were susceptible to carbapenems, a class of powerful drugs usually held back for serious infections, and only 23–27% to third-generation cephalosporins.
- Acinetobacter baumannii: 91.1% of revived samples were resistant to carbapenems.
- Staphylococcus aureus: The share of methicillin-resistant samples (MRSA) was 56.8%.
- Typhoid: Ciprofloxacin worked against only 2.0% of Salmonella Typhi samples.
Is there any good news?
Yes, some older and cheaper drugs still work well for specific infections. Salmonella Typhi remained highly susceptible to azithromycin (99.4%), ceftriaxone (96.6%) and trimethoprim-sulfamethoxazole (97.1%). For bladder infections caused by E. coli, nitrofurantoin (79.1%) and fosfomycin (96.5%) still performed well, and the report names them as the drugs of choice for cystitis. Against MRSA, vancomycin, teicoplanin and tigecycline showed 100% activity in laboratory tests.
What changes in smaller hospitals?
The new secondary-care data show that resistance to cephalosporins and fluoroquinolones is common regardless of hospital size, while carbapenem resistance is mostly a problem of bigger hospitals. In E. coli, ceftriaxone susceptibility fell from 39.8% in hospitals with up to 200 beds to 11.5% in hospitals with 500 or more beds.
Dr Kamini Walia, Scientist G and head of ICMR's Division of Descriptive Research, which runs the network, told The Indian Express on 18 November 2026 that routine infections becoming harder to treat is no longer a future risk. "We have already reached that point," she said, adding that the main driver is the misuse of antibiotics, including for viral illnesses where they do not work.
Why it matters for patients
When first-line drugs fail, doctors have to move to "last resort" antibiotics that are costlier, carry more side effects and may be less effective. The report also, for the first time, presents separate data on bloodstream infections in newborns, where Klebsiella pneumoniae was the most common cause and showed low susceptibility to third-generation cephalosporins and carbapenems.
The report's advice to doctors includes avoiding fluoroquinolones such as norfloxacin and ofloxacin, and cephalosporins such as cefixime, as a first guess for diarrhoea, avoiding quinolones and third-generation cephalosporins for upper urinary infections, and not using carbapenems routinely for typhoid. Dr Walia called for compulsory antimicrobial stewardship programmes in all hospitals and encouraged adult vaccination against flu, typhoid and pneumococcal infections.
What happens next?
The findings come as the Centre moves on several fronts. The Health Ministry has proposed draft rules to bring antimicrobials under central regulatory oversight, and the Central Council for Research in Homoeopathy has launched a national awareness campaign telling people that antibiotics do not cure colds or flu. Dr Walia said ICMR is still analysing nationwide data from neonatal intensive-care units, which may lead to changes in treatment protocols for newborns.
For ordinary readers, the message from ICMR's scientists is to avoid antibiotics for illnesses that do not need them, such as most viral fevers and many cases of diarrhoea, and to rely on a doctor's judgement and laboratory tests.




